BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more
BB Biotech AG (BION) - Total Assets
Latest total assets as of June 2025: CHF1.84 Billion CHF
Based on the latest financial reports, BB Biotech AG (BION) holds total assets worth CHF1.84 Billion CHF as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BB Biotech AG - Total Assets Trend (2003–2024)
This chart illustrates how BB Biotech AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BB Biotech AG - Asset Composition Analysis
Current Asset Composition (December 2024)
BB Biotech AG's total assets of CHF1.84 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF458.00K | 0.0% |
| Accounts Receivable | CHF0.00 | 0.0% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how BB Biotech AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BB Biotech AG's current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is cash and equivalents at 0.0% of total assets.
BB Biotech AG Competitors by Total Assets
Key competitors of BB Biotech AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BB Biotech AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BB Biotech AG generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, BB Biotech AG generates $ 3.15 in net profit.
BB Biotech AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 758.29 | 8.40 | 13.95 |
| Quick Ratio | 758.29 | 8.40 | 13.95 |
| Cash Ratio | 0.89 | 0.00 | 0.00 |
| Working Capital | CHF1.84 Billion | CHF 2.39 Billion | CHF 3.23 Billion |
BB Biotech AG - Advanced Valuation Insights
This section examines the relationship between BB Biotech AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | CHF2.41 Billion |
| Market Capitalization | $495.17K USD |
Valuation Analysis
Below Book Valuation: The market values BB Biotech AG's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BB Biotech AG's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BB Biotech AG (2003–2024)
The table below shows the annual total assets of BB Biotech AG from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF2.41 Billion | -8.71% |
| 2023-12-31 | CHF2.64 Billion | -13.63% |
| 2022-12-31 | CHF3.05 Billion | -16.21% |
| 2021-12-31 | CHF3.64 Billion | -8.05% |
| 2020-12-31 | CHF3.96 Billion | +11.49% |
| 2019-12-31 | CHF3.55 Billion | +15.15% |
| 2018-12-31 | CHF3.09 Billion | -15.15% |
| 2017-12-31 | CHF3.64 Billion | +12.76% |
| 2016-12-31 | CHF3.23 Billion | -22.14% |
| 2015-12-31 | CHF4.14 Billion | +17.29% |
| 2014-12-31 | CHF3.53 Billion | +59.79% |
| 2013-12-31 | CHF2.21 Billion | +60.91% |
| 2012-12-31 | CHF1.37 Billion | +19.31% |
| 2011-12-31 | CHF1.15 Billion | -16.37% |
| 2010-12-31 | CHF1.38 Billion | -9.46% |
| 2009-12-31 | CHF1.52 Billion | -6.07% |
| 2008-12-31 | CHF1.62 Billion | -22.04% |
| 2007-12-31 | CHF2.08 Billion | -18.67% |
| 2006-12-31 | CHF2.55 Billion | +2.22% |
| 2005-12-31 | CHF2.50 Billion | +30.25% |
| 2004-12-31 | CHF1.92 Billion | -3.26% |
| 2003-12-31 | CHF1.98 Billion | -- |